Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR3 | P49019 | 3/20 | 0.65 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.60 |
| ▸ | HPGD | P15428 | 4/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 2/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.56 |
| ▸ | NPC1 | O15118 | 2/20 | 0.56 |
| ▸ | TP53 | P04637 | 2/20 | 0.56 |
| ▸ | RAB9A | P51151 | 2/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | NAMPT | P43490 | 1/20 | 0.54 |
| ▸ | THRB | P10828 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.50 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7330424 | 0.98 | HCAR3 (0.63) | HCAR3FGFR1HPGDKMT2AALDH1A1 | |
| SCHEMBL30937457 | 0.90 | HCAR3 (0.61) | HCAR3FGFR1HPGDKMT2AALDH1A1 | |
| SCHEMBL16149721 | 0.87 | KMT2A (0.52) | HCAR3FGFR1HPGDKMT2AALDH1A1 | |
| SCHEMBL16755644 | 0.87 | KMT2A (0.55) | HCAR3FGFR1HPGDKMT2AALDH1A1 | |
| SCHEMBL1869730 | 0.86 | FGFR1 (0.60) | HCAR3FGFR1HPGDKMT2AALDH1A1 | |
| SCHEMBL6112848 | 0.86 | ALDH1A1 (0.65) | HCAR3FGFR1HPGDKMT2AALDH1A1 | |
| SCHEMBL1299105 | 0.85 | FGFR1 (0.60) | HCAR3FGFR1HPGDKMT2AALDH1A1 | |
| SCHEMBL14061238 | 0.85 | NPC1 (0.57) | HCAR3FGFR1HPGDKMT2AALDH1A1 | |
| SCHEMBL14150124 | 0.85 | NPC1 (0.57) | HCAR3FGFR1HPGDKMT2AALDH1A1 | |
| Hydrochloric Acid SCHEMBL6112989 | 0.83 | NPC1 (0.56) | HCAR3FGFR1HPGDKMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 183 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025202864-A1 | ENT1 INHIBITORS IN COMBINATION WITH ONCOLYTIC VIRUSES AND THEIR USE IN THE TREATMENT OF CANCER | iTeos Belgium SA (BE) | 2025-10-02 | — | — | WO | claimed |
| WO-2025126110-A1 | ENT1 INHIBITORS IN COMBINATION WITH BISPECIFIC ANTIBODIES | iTeos Belgium SA (BE) | 2025-06-19 | — | — | WO | claimed |
| WO-2025104613-A1 | ENT1 INHIBITORS IN COMBINATION WITH CHECKPOINT INHIBITORS | iTeos Belgium SA (BE) | 2025-05-22 | — | — | WO | claimed |
| CN-118146163-A | Benzimidazole derivative and preparation method thereof | 雅安职业技术学院 | 2024-06-07 | — | — | CN | claimed |
| CN-116535365-A | Macrocyclic diamine derivatives and their combination with adenosine receptor antagonists as ENT inhibitors for the treatment of cancer | ITEOS比利时公司 | 2023-08-04 | — | — | CN | claimed |
| US-20230203058-A1 | MACROCYCLIC DIAMINE DERIVATIVES AS ENT INHIBITORS FOR THE TREATMENT OF CANCERS, AND COMBINATION THEREOF WITH ADENOSINE RECEPTOR ANTAGONISTS | iTeos Belgium SA (BE) | 2023-06-29 | — | — | US | claimed |
| CN-111511731-B | Olefin compounds as modulators of the farnesol X receptor | 百时美施贵宝公司 | 2023-05-23 | — | — | CN | claimed |
| US-20110105491-A1 | THIAZOLIDINE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-05-05 | — | — | US | claimed |
| WO-2010004507-A1 | THIAZOLIDINE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2010-01-14 | — | — | WO | claimed |
| WO-2025202864-A1 | ENT1 INHIBITORS IN COMBINATION WITH ONCOLYTIC VIRUSES AND THEIR USE IN THE TREATMENT OF CANCER | iTeos Belgium SA (BE) | 2025-10-02 | — | — | WO | disclosed |
| WO-2025126110-A1 | ENT1 INHIBITORS IN COMBINATION WITH BISPECIFIC ANTIBODIES | iTeos Belgium SA (BE) | 2025-06-19 | — | — | WO | disclosed |
| WO-2025104613-A1 | ENT1 INHIBITORS IN COMBINATION WITH CHECKPOINT INHIBITORS | iTeos Belgium SA (BE) | 2025-05-22 | — | — | WO | disclosed |
| US-20250136592-A1 | C-LINKED INHIBITORS OF ENL/AF9 YEATS | BRIDGE MEDICINES | 2025-05-01 | — | — | US | disclosed |
| WO-2025076284-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USING THE SAME | DELPHIA THERAPEUTICS, INC. (US) | 2025-04-10 | — | — | WO | disclosed |
| WO-2005030704-A1 | INHIBITORS OF HISTONE DEACETYLASE | METHYLGENE, INC. (CA) | 2005-04-07 | — | — | WO | disclosed |
| WO-2005030704-A1 | INHIBITORS OF HISTONE DEACETYLASE | METHYLGENE, INC. (CA) | 2005-04-07 | — | — | WO | disclosed |
| US-20050054710-A1 | Indolinones substituted by heterocycles, the preparation thereof and their use as medicaments | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2005-03-10 | — | — | US | disclosed |
| US-20050009054-A1 | Compounds having a fused, bicyclic moiety for binding to the minor groove of dsDNA | PHARMACIA CORPORATION | 2005-01-13 | — | — | US | disclosed |
| WO-2004099131-A2 | COMPOUNDS HAVING A FUSED, BICYCLIC MOIETY FOR BINDING TO THE MINOR GROOVE OF DSDNA | PHARMACIA CORPORATION (US) | 2004-11-18 | — | — | WO | disclosed |
| WO-2004026829-A2 | HETEROCYCLICALLY SUBSTITUTED INDOLINONES AND THEIR USE AS RECEPTOR TYROSINE KINASE INHIBITORS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105491-A1 | THIAZOLIDINE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, OXTR | HCAR3 112/4885FGFR1 202/4885HPGD 2597/4885 |
| US-20230203058-A1 | MACROCYCLIC DIAMINE DERIVATIVES AS ENT INHIBITORS FOR THE TREATMENT OF CANCERS, AND COMBINATION THEREOF WITH ADENOSINE RECEPTOR ANTAGONISTS | ENTPD1, SLC29A1, ENTPD5 | HCAR3 269/4885FGFR1 374/4885HPGD 1486/4885 |
| US-20050054710-A1 | Indolinones substituted by heterocycles, the preparation thereof and their use as medicaments | CDK1, CDK2, CDK3 | HCAR3 1434/4885FGFR1 147/4885HPGD 1038/4885 |
| US-20050009054-A1 | Compounds having a fused, bicyclic moiety for binding to the minor groove of dsDNA | PCNA, POLM, PBRM1 | HCAR3 1653/4885FGFR1 906/4885HPGD 2228/4885 |
| US-20250136592-A1 | C-LINKED INHIBITORS OF ENL/AF9 YEATS | MLLT3, MLLT1, YEATS2 | HCAR3 2931/4885FGFR1 1521/4885HPGD 4028/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.